Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa

AIDS Patient Care and STDs

Volumn 25, Issue 3, 2011, Pages 163-170

  Chaiyachati, Krisda ^a,b,c   Hirschhorn, Lisa R ^d,e   Tanser, Frank ^b   Newell, Marie Louise ^b,f   Bärnighausen, Till ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e JSI RESEARCH AND TRAINING INSTITUTE   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DATA COLLECTION METHOD; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIKERT SCALE; MAJOR CLINICAL STUDY; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; RATING SCALE; RISK FACTOR; RURAL POPULATION; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TREATMENT REFUSAL; VALIDATION STUDY; VIRUS LOAD; VISUAL ANALOG SCALE;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PUBLIC HEALTH; REPRODUCIBILITY OF RESULTS; RURAL POPULATION; SOUTH AFRICA;

EID: 79952525346     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0257     Document Type: Article

References (58)

1. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-1423. (Pubitemid 32955198)
2. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366. (Pubitemid 30182431)
3. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-395. (Pubitemid 30431595)
4. Haubrich RH, Little SJ, Currier JS, et al. The value of patientreported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999;13:1099-1107. (Pubitemid 29361401)
5. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virusinfected persons in clinical trials. Clin Infect Dis 2002;34:1115-1121. (Pubitemid 34289685)
6. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis 2001;33:700-705. (Pubitemid 32762944)
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30. (Pubitemid 30432540)
8. Hecht FM. Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998;10:57-59.
9. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. J Acquir Immune Defic Syndr 2005;38:445-448. (Pubitemid 40381555)
10. Deschamps AE, De Geest S, Vandamme AM, Bobbaers H, Peetermans WE, Van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDs 2008;22:735-743.
11. World Health Organization, UNAIDS., UNICEF. Towards universal access: scaling up priority HIV/AIDS interventios in the health sector: Progress report 2009. Geneva: World Health Organization, 2009.
12. World Health Organization. Dept. of HIV/AIDS., Interim WHO Antiretroviral Treament Working Group. Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach. Geneva: World Health Organization, 2006.
13. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 2006;10:227-245.
14. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008;197(Suppl 3): S272-278. (Pubitemid 351717317)
15. Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS 2002;16:1835-1837.
16. Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med 2010;152:18-25.
17. National Department of Health. Clinical guidelines for the management of HIV & AIDS in adults and adolescents. Pretoria, South Africa: National Department of Health, 2010.
18. Llabre MM, Weaver KE, Duran RE, Antoni MH, McPherson-Baker S, Schneiderman N. A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults. AIDS Patient Care STDs 2006;20:701-711. (Pubitemid 46141369)
19. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA 2006;296:679-690. (Pubitemid 44200639)
20. Jones DL, McPherson-Baker S, Lydston D, et al. Efficacy of a group medication adherence intervention among HIV positive women: The SMART/EST Women's Project. AIDS Behav 2007;11:79-86. (Pubitemid 46147354)
21. Jones DL, Ishii M, LaPerriere A, et al. Influencing medication adherence among women with AIDS. AIDS Care 2003;15:463-474. (Pubitemid 36871787)
22. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 2007;46:238-244. (Pubitemid 47482621)
23. Mugusi F, Mugusi S, Bakari M, et al. Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries: The Tanzanian experience. Trop Med Int Health 2009;14:1226-1232.
24. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resourcelimited setting. J Acquir Immune Defic Syndr 2004;36:1100-1102. (Pubitemid 38989377)
25. Rougemont M, Stoll BE, Elia N, Ngang P. Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: A prospective study at Yaounde Central Hospital, Cameroon. AIDS Res Ther 2009;6:21.
26. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161:1962-1968.
27. Hugen PW, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 2002;30:324-334. (Pubitemid 34774081)
28. Kouanfack C, Laurent C, Peytavin G, et al. Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon. J Acquir Immune Defic Syndr 2008;48:216-219.
29. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr 2006;43(Suppl 1): S149-155. (Pubitemid 44885655)
30. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:435-442. (Pubitemid 32489021)
31. Houlihan CF, Bland RM, Mutevedzi PC, et al. Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol (in press).
32. Mutevedzi PC, Lessells RJ, Heller T, Bärnighausen T, Cooke GS, Newell ML. Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: Does rapid expansion affect patient outcomes? Bull World Health Organ 2010;88:593-600.
33. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2006 revision. Geneva: World Health Organization, 2006.
34. Machtinger EL, Bangsberg DR. Adherence to HIV antiretroviral therapy. http://hivinsite.ucsf.edu/insite?page = kb-03-02-09 (Las accessed November 15, 2010).
35. Sullivan Pepe M. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press, 2003.
36. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. Infect Genet Evol 2007;7:333-342. (Pubitemid 46187499)
37. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007;21:965-971. (Pubitemid 46684328)
38. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One 2008;3: e2783.
39. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004;38:1311-1316. (Pubitemid 38608576)
40. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: Insights from empirical data and theoretical models. AIDS 2005;19:1-14. (Pubitemid 40111013)
41. Huang KH, Goedhals D, Fryer H, et al. Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa. Antivir Ther 2009;14:975-984.
42. Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008;13:625-639.
43. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicinbased antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008;61:389-393.
44. Onyebujoh PC, Ribeiro I, Whalen CC. Treatment options for HIV-associated tuberculosis. J Infect Dis 2007;196(Suppl 1): S35-45. (Pubitemid 47206083)
45. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008;300:530-539.
46. Brantley RK, Williams KR, Silva TM, et al. AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Braz J Infect Dis 2003;7:16-22.
47. Lackner AA, Mohan M, Veazey RS. The gastrointestinal tract and AIDS pathogenesis. Gastroenterology 2009;136:1965-1978.
48. Mills E, Cooper C, Seely D, Kanfer I. African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J 2005;4:19.
49. Truter I. African traditional healers. SA Pharamaceut J 2007 (September): 56-60.
50. Garcia F, Alonso MM, Romeu J, et al. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study. J Acquir Immune Defic Syndr 2000;25:26-35.
51. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007;4:65-72. (Pubitemid 46806622)
52. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45:4-8. (Pubitemid 46684437)
53. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941. (Pubitemid 44435526)
54. Orrell C, Harling G, Lawn SD, et al. Conservation of firstline antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007;12:83-88. (Pubitemid 46340429)
55. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008;5: e109.
56. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-977. (Pubitemid 32466236)
57. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav 2008;12:86-94. (Pubitemid 351143454)
58. Walshe L, Saple DG, Mehta SH, Shah B, Bollinger RC, Gupta A. Physician estimate of antiretroviral adherence in India: Poor correlation with patient self-report and viral load. AIDS Patient Care STDs 2010;24:189-195.